FDA Creates Independent CBER Safety Council for Vaccines and Gene Therapies

By The Indus Pulse Editorial Team3 min read
Frosted glass vaccine vials, micropipettes, and syringes arranged on a metal workbench inside a cleanroom
AI illustrationCreated for The Indus Pulse with AI tools

The US Food and Drug Administration (FDA) has established a new internal oversight body, the Center for Biologics Evaluation and Research (CBER) Safety Council, to separate post-market safety reviews from the offices that approve biologic products. Taking effect on Thursday, November 19, 2026, according to an FDA notice, the council replaces CBER's previous Safety Working Group and oversees vaccines, blood products, and cell and gene therapies after market launch.

Independent Structure and Mandate

Unlike the product offices that evaluate premarket applications, the CBER Safety Council reports directly to CBER Director Karim Mikhail and is led by a Senior Advisor for Postmarketing Safety. According to an FDA notice cited by Fierce Pharma, the unit is designed to deliver post-approval oversight through "a dedicated, cross-functional team with clear lines of accountability." Analytical backing for the panel will come from the CBER Surveillance Program, the Division of Analytics and Benefit-Risk Assessment, and the Division of Pharmacovigilance.

The council's mandate includes reviewing emerging safety signals, conducting benefit-risk assessments, recommending safety labelling changes, risk evaluation and mitigation strategies, and post-market studies, and advising on potential market withdrawals. It is also tasked with publishing public safety communications promptly after major safety determinations. Additional details on the council's membership, structure, and operating procedures will be released later.

Surveillance Tools and Gene Therapy Impact

Outside the agency, the council plans to work alongside the National Institutes of Health and the US Centers for Disease Control and Prevention, tapping surveillance databases including the FDA Sentinel program and the Vaccine Adverse Event Reporting System (VAERS). PharmTech.com noted that rapid regulatory expansion in cell and gene therapies throughout 2026, including June rare-disease guidance and recent approvals such as Ultragenyx's GENGLYCOS and a paediatric sickle cell gene therapy, has shifted more evidence gathering to the post-approval period. However, PharmTech.com pointed out that it remains unclear how tools like VAERS and Sentinel will be applied to gene therapies administered to small patient populations.

FDA Leadership Context

The launch follows significant leadership turnover at the agency, including former commissioner Marty Makary's departure in May, leaving Kyle Diamantas as acting commissioner, and earlier CBER departures involving Peter Marks, Vinay Prasad, and Katherine Szarama. Mikhail became permanent CBER director in September after serving in an acting role since May, telling Fierce Pharma in October that making decisions public to enhance public trust was a top priority. Earlier this week, the White House withdrew its nomination of Heidi Overton for FDA commissioner hours before a scheduled Senate confirmation vote following early November midterm election shifts and a contentious September Senate HELP Committee hearing.

Background

In 2025, CBER granted accelerated approval to Avance Nerve Graft (acellular nerve allograft-arwx) for sensory nerve discontinuity >25mm and mixed and motor nerve discontinuity, according to U.S. Food and Drug Administration.

Under CBER's prior postmarket process, a September 30, 2022 FDA assessment found that nearly half of the safety signals in the CBER cohort reached phase 3, with therapeutic products accounting for the majority and FAERS as the most common signal source.

In May 2005, the FDA created the Drug Safety Oversight Board within CDER, later mandated by law in the FDA Amendments Act of 2007, to provide independent oversight and advice to the Center Director on drug safety issues, though critics warned that limiting membership to federal employees could exclude the public from board proceedings, according to Congressional Research Service (via EveryCRSReport).

On October 30, 2026, the FDA granted accelerated approval to VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), a plasmid DNA-based immunotherapy listed on CBER's Approved Cellular and Gene Therapy Products page, according to U.S. Food and Drug Administration.

Spotted an error in this article? Tell us and we will check it.